JP2012515748A5 - - Google Patents

Download PDF

Info

Publication number
JP2012515748A5
JP2012515748A5 JP2011546797A JP2011546797A JP2012515748A5 JP 2012515748 A5 JP2012515748 A5 JP 2012515748A5 JP 2011546797 A JP2011546797 A JP 2011546797A JP 2011546797 A JP2011546797 A JP 2011546797A JP 2012515748 A5 JP2012515748 A5 JP 2012515748A5
Authority
JP
Japan
Prior art keywords
growth hormone
hormone compound
seq
compound according
hgh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011546797A
Other languages
English (en)
Japanese (ja)
Other versions
JP5816097B2 (ja
JP2012515748A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2010/050725 external-priority patent/WO2010084173A1/en
Publication of JP2012515748A publication Critical patent/JP2012515748A/ja
Publication of JP2012515748A5 publication Critical patent/JP2012515748A5/ja
Application granted granted Critical
Publication of JP5816097B2 publication Critical patent/JP5816097B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011546797A 2009-01-22 2010-01-22 安定な成長ホルモン化合物 Active JP5816097B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP09151108.9 2009-01-22
EP09151108 2009-01-22
US14811909P 2009-01-29 2009-01-29
US61/148,119 2009-01-29
PCT/EP2010/050725 WO2010084173A1 (en) 2009-01-22 2010-01-22 Stable growth hormone compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015133685A Division JP2015193636A (ja) 2009-01-22 2015-07-02 安定な成長ホルモン化合物

Publications (3)

Publication Number Publication Date
JP2012515748A JP2012515748A (ja) 2012-07-12
JP2012515748A5 true JP2012515748A5 (OSRAM) 2013-01-17
JP5816097B2 JP5816097B2 (ja) 2015-11-18

Family

ID=40521462

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011546797A Active JP5816097B2 (ja) 2009-01-22 2010-01-22 安定な成長ホルモン化合物
JP2015133685A Withdrawn JP2015193636A (ja) 2009-01-22 2015-07-02 安定な成長ホルモン化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015133685A Withdrawn JP2015193636A (ja) 2009-01-22 2015-07-02 安定な成長ホルモン化合物

Country Status (14)

Country Link
US (1) US8513192B2 (OSRAM)
EP (1) EP2389389B1 (OSRAM)
JP (2) JP5816097B2 (OSRAM)
KR (1) KR20110122100A (OSRAM)
CN (1) CN102292349B (OSRAM)
AU (1) AU2010207725B2 (OSRAM)
CA (1) CA2747825A1 (OSRAM)
ES (1) ES2542202T3 (OSRAM)
IL (1) IL213686A0 (OSRAM)
MX (1) MX2011007736A (OSRAM)
RU (1) RU2539797C2 (OSRAM)
TW (1) TWI504405B (OSRAM)
WO (1) WO2010084173A1 (OSRAM)
ZA (1) ZA201105419B (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds
WO2011015649A1 (en) 2009-08-06 2011-02-10 Novo Nordisk Health Care Ag Growth hormones with prolonged in-vivo efficacy
SI2525834T1 (sl) * 2010-01-22 2019-10-30 Novo Nordisk Healthcare Ag Rastni hormoni s podaljšano in vivo učinkovitostjo
JP5980689B2 (ja) * 2010-01-22 2016-08-31 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 安定な成長ホルモン化合物
CN103269720A (zh) * 2010-07-22 2013-08-28 诺沃—诺迪斯克保健股份有限公司 生长激素缀合物
EP2981282B1 (en) 2013-04-05 2020-11-04 Novo Nordisk Health Care AG Growth hormone compound formulation
EP4262833A4 (en) * 2020-12-18 2024-11-20 The General Hospital Corporation PROBIOTICS COMPOSITIONS AND METHODS OF USE THEREOF TO IMPROVE GROWTH AND SOCIAL FUNCTION IN CHILDREN

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GB8610551D0 (en) 1986-04-30 1986-06-04 Hoffmann La Roche Polypeptide & protein derivatives
JPH0665280B2 (ja) 1987-03-04 1994-08-24 味の素株式会社 タンパクゲル化剤及びそれを用いるタンパクのゲル化方法
ATE198353T1 (de) * 1988-08-24 2001-01-15 American Cyanamid Co Stabilisierung von somatotropinen durch modifikation von cystein-resten durch orts- spezifische mutagenese oder chemische derivatisierung
CA2001774C (en) 1988-10-28 2001-10-16 James A. Wells Method for identifying active domains and amino acid residues in polypeptides and hormone variants
US6780613B1 (en) 1988-10-28 2004-08-24 Genentech, Inc. Growth hormone variants
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
EP0464022B1 (en) 1989-03-20 2000-05-31 The General Hospital Corporation Insulinotropic hormone
US5101018A (en) * 1989-06-12 1992-03-31 International Minerals & Chemical Corp. Method for recovering recombinant proteins
DE3930696A1 (de) 1989-09-14 1991-03-28 Hoechst Ag Gallensaeurederivate, verfahren zu ihrer herstellung, verwendung als arzneimittel
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
EP0512042B1 (en) 1990-01-24 1998-04-08 BUCKLEY, Douglas I. Glp-1 analogs useful for diabetes treatment
US5951972A (en) 1990-05-04 1999-09-14 American Cyanamid Company Stabilization of somatotropins and other proteins by modification of cysteine residues
JP2849773B2 (ja) 1990-08-27 1999-01-27 天野製薬株式会社 ストレプトミセス属由来のトランスグルタミナーゼの製造法
DK220890D0 (da) 1990-09-14 1990-09-14 Ole Buchardt Fremgangsmaade til fremstilling af c-terminalt amiderede peptider
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
IT1251895B (it) 1991-09-27 1995-05-26 Eniricerche Spa Mutanti dell'ormone della crescita umano e loro impiego
EP0555649B1 (en) 1992-01-14 2004-12-08 Ajinomoto Co., Inc. Gene encoding transglutaminase derived from fish
ZA936811B (en) 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
US5359030A (en) 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
EP0693556B1 (en) 1994-01-28 2004-10-06 Ajinomoto Co., Inc. Transglutaminase originating in japanese oyster
DE69535037T2 (de) 1994-08-26 2006-12-07 Novozymes A/S Mikrobielle transglutaminasen, ihre herstellung und ihre verwendung
US6010871A (en) 1994-09-29 2000-01-04 Ajinomoto Co., Inc. Modification of peptide and protein
DE4437604A1 (de) 1994-10-21 1996-04-25 Basf Ag Konjugate aus einem Poly- oder Oligopeptid und einer niedermolekularen lipophilen Verbindung
DE69629719T2 (de) 1995-01-19 2004-07-08 Novozymes A/S Transglutaminasen aus oomyzeten
JP3669390B2 (ja) 1995-02-09 2005-07-06 味の素株式会社 バチルス属細菌由来のトランスグルタミナーゼ
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
DK0851925T3 (da) 1995-09-21 2005-11-28 Genentech Inc Humane Væksthormonvarianter
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
ES2283025T3 (es) 1996-08-30 2007-10-16 Novo Nordisk A/S Derivados de glp-1.1.
AU4112497A (en) 1996-08-30 1998-03-19 Novo Nordisk A/S Glp-2 derivatives
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
WO1998013381A1 (fr) 1996-09-26 1998-04-02 Ajinomoto Co., Inc. Proteines modifiees physiologiquement actives et compositions medicamenteuses les contenant
US5985627A (en) 1997-02-28 1999-11-16 Carlsberg Laboratory Modified carboxypeptidase
JPH1156378A (ja) * 1997-06-11 1999-03-02 Nippon Chem Res Kk 変異型ヒト成長ホルモンとその用途
EP0996629B1 (en) * 1997-06-25 2006-08-02 Applied Research Systems Ars Holding N.V. Disulfide crosslinked glycoprotein hormone analogs, their preparation and use
IL133974A0 (en) 1997-07-14 2001-04-30 Bolder Biotechnology Inc Derivatives of growth hormone and related proteins
US6136536A (en) 1997-10-29 2000-10-24 Genetics Institute, Inc. Rapid generation of stable mammalian cell lines producing high levels of recombinant proteins
WO1999043705A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally truncated glp-1 derivatives
EP1060192A2 (en) 1998-02-27 2000-12-20 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
JP2002504518A (ja) 1998-02-27 2002-02-12 ノボ ノルディスク アクティーゼルスカブ 部分的に構造化されたミセルー様凝集体を形成する、２５％を超えるヘリックス−含有率を有するｇｌｐ−１誘導体
US6656922B2 (en) 1998-05-28 2003-12-02 Mediplex Corporation, Korea Oral delivery of macromolecules
US6358705B1 (en) 1998-07-16 2002-03-19 Novo Nordisk A/S Method of making proteins in transformed yeast cells
DE69922043T2 (de) 1998-12-07 2005-11-24 Société de Conseils de Recherches et d'Applications Scientifiques S.A.S. Glp-1 analoge
CN1191273C (zh) 1999-05-17 2005-03-02 康久化学公司 长效促胰岛肽
US6309663B1 (en) 1999-08-17 2001-10-30 Lipocine Inc. Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
WO2001004287A1 (en) 1999-07-07 2001-01-18 Maxygen Aps A method for preparing modified polypeptides
EP1076066A1 (en) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides for lowering blood glucose levels
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US20040001827A1 (en) 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
AU2353701A (en) 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
PL206148B1 (pl) 2000-02-11 2010-07-30 Bayer HealthCare LLCBayer HealthCare LLC Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US20020142964A1 (en) 2000-11-02 2002-10-03 Nissen Torben Lauesgaard Single-chain polypeptides
EP1355942B1 (en) 2000-12-07 2008-08-27 Eli Lilly And Company Glp-1 fusion proteins
US20060183197A1 (en) 2001-01-11 2006-08-17 Andersen Kim V Variant growth hormone molecules conjugated with macromolecules compounds
WO2002055532A2 (en) 2001-01-11 2002-07-18 Maxygen Aps Variant growth hormone molecules conjugated with macromolecular compounds
FR2819810B1 (fr) 2001-01-23 2004-05-28 Pf Medicament Peptides non glycosyles derives de la proteine g du vrs et leur utilisation dans un vaccin
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
AU2002310438B2 (en) * 2001-06-14 2008-05-01 The Scripps Research Institute Stabilized proteins with engineered disulfide bonds
JP5562510B2 (ja) 2001-06-28 2014-07-30 ノヴォ ノルディスク アー／エス 修飾ｇｌｐ−１の安定な処方剤
US7186797B2 (en) 2001-08-10 2007-03-06 Epix Pharmaceuticals, Inc. Polypeptide conjugates with extended circulating half-lives
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
MXPA04004809A (es) 2001-11-20 2004-08-11 Pharmacia Corp Conjugados de hormona de crecimiento humana modificada quimicamente.
JP2003199569A (ja) 2001-12-17 2003-07-15 Food Industry Research & Development Inst ストレプトベルティシリウム・ラダカヌムのトランスグルタミナーゼ遺伝子及び該遺伝子によってコードされるトランスグルタミナーゼ
US20050100963A1 (en) 2002-03-01 2005-05-12 Dyax Corporation KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
NZ535684A (en) 2002-04-10 2006-03-31 Lilly Co Eli Use of a GLP-1 (glucagon like peptide-1) compound to treat gastroparesis by increasing gastric emptying
RU2004134726A (ru) 2002-04-30 2005-06-10 Максиджен Холдингз Лтд. (Ky) Варианты полипептида фактора vii или viia
US7611700B2 (en) 2002-09-09 2009-11-03 Hanall Pharmaceuticals, Co., Ltd. Protease resistant modified interferon alpha polypeptides
WO2004074315A2 (en) 2003-02-19 2004-09-02 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Analogues of glp-1
WO2004099246A2 (en) 2003-05-09 2004-11-18 Novo Nordisk A/S Peptides for use in treating obesity
WO2005014035A2 (en) 2003-08-08 2005-02-17 Novo Nordisk Health Care Ag Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest
RU2401276C2 (ru) 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
WO2005028516A2 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
WO2005035553A2 (en) 2003-10-10 2005-04-21 Novo Nordisk A/S Conjugation of peptides
MXPA06006746A (es) 2003-12-18 2006-08-18 Novo Nordisk As Analogos de glp-1 novedosos ligados a agentes similares a albumina.
WO2005058954A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel glp-1 compounds
EP2368579A1 (en) 2004-01-21 2011-09-28 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
BRPI0507169A (pt) * 2004-02-02 2007-06-26 Ambrx Inc polipeptìdeos do hormÈnio de crescimento humano modificados e seu usos
US7906137B2 (en) 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
WO2006013202A2 (en) 2004-08-02 2006-02-09 Novo Nordisk Health Care Ag Conjugation of fvii
WO2006037810A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted glp-1 compounds
US7998930B2 (en) * 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
AU2006224537A1 (en) 2005-03-18 2006-09-21 Novo Nordisk A/S Extended GLP-1 compounds
JP2008533104A (ja) 2005-03-18 2008-08-21 ノボ ノルディスク アクティーゼルスカブ Ｇｌｐ−１受容体の二量体ペプチドアゴニスト
EP2360170A3 (en) 2005-06-17 2012-03-28 Novo Nordisk Health Care AG Selective reduction and derivatization of engineered proteins comprinsing at least one non-native cysteine
WO2007020291A1 (en) 2005-08-18 2007-02-22 Novo Nordisk Health Care Ag Improving transglutaminase substrate specificity
EP1986694B1 (en) 2006-02-14 2015-06-10 Novo Nordisk Health Care AG Coupling of polypeptides at the c-terminus
MX2008016169A (es) 2006-07-07 2009-01-15 Novo Nordisk Healthcare Ag Nuevos conjugados de proteina y metodos para su preparacion.
WO2008014430A1 (en) 2006-07-27 2008-01-31 Emisphere Technologies, Inc. Arylsulfanyl compounds and compositions for delivering active agents
CN101506233A (zh) 2006-08-18 2009-08-12 诺沃-诺迪斯克保健股份有限公司 具有提高的特异性的转谷氨酰胺酶变异体
US20080095837A1 (en) 2006-08-31 2008-04-24 Emisphere Technologies, Inc. Human growth hormone formulations
EP2059260B1 (en) 2006-08-31 2013-06-19 Novartis AG Pharmaceutical compositions comprising hGH for oral delivery
JP5390404B2 (ja) 2007-02-16 2014-01-15 エミスフェアー・テクノロジーズ・インク 活性薬剤を送達するための環状部分を有する化合物及び組成物
WO2008112836A2 (en) 2007-03-15 2008-09-18 Novartis Ag Pharmaceutical composition comprising human growth hormon
EP2190460B1 (en) 2007-09-05 2014-12-17 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN102112157B (zh) 2008-08-06 2013-05-29 诺沃-诺迪斯克保健股份有限公司 具有延长的体内效能的缀合蛋白
CN106317164A (zh) 2008-09-12 2017-01-11 诺沃—诺迪斯克有限公司 酰化肽或蛋白的方法
EP2389389B1 (en) 2009-01-22 2015-04-15 Novo Nordisk Health Care AG Stable growth hormone compounds

Similar Documents

Publication Publication Date Title
JP2012515748A5 (OSRAM)
JP2013518037A5 (OSRAM)
MY158627A (en) Halogen-stabilized insulin
WO2010123290A3 (ko) 체내 지속성을 유지함으로 체내 반감기가 증가된 단백질 또는 펩티드 융합체, 및 이를 이용하여 체내 반감기를 증가시키는 방법
PH12012501135A1 (en) Insulin analogues with chlorinated amino acids
NZ608502A (en) Polypeptides that bind to human complement component c5
MX370861B (es) Mutantes profactor de crecimiento del nervio (ngf) novedosos y usos de los mismos en la producción de factor de crecimiento del nervio beta.
NZ590050A (en) Fgf21 mutants and uses thereof
NZ602471A (en) Antagonists of activin-actriia and uses for increasing red blood cell levels
TW201209062A (en) Amide based glucagon superfamily peptide prodrugs
MY189079A (en) Insulin analogues with chlorinated amino acids
NZ603883A (en) Method for preparing antibodies having improved properties
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
RU2011133926A (ru) Стабилизированные гормоны роста
NZ717030A (en) Growth differentiation factor 15 (gdf-15) constructs
NZ595387A (en) Peptides for treatment and diagnosis of autoimmune disease
WO2012069836A3 (en) Biologically active complex and its preparation
NZ611878A (en) Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
JP2005537234A5 (OSRAM)
NZ601591A (en) Methods for treating pancreatic cancer
JP2018510132A5 (OSRAM)
NZ603200A (en) Peptides and their use
NZ602693A (en) Immunogenic proteins and compositions for the treatment and prevention of streptococcus agalactiae
NZ708091A (en) Stabilized insulin-like growth factor polypeptides
EP4349361A3 (en) Peptide exhibiting wrinkle-improving activity and uses thereof